Editing Tocolytic (section)

==Future direction of tocolytics==
Most tocolytics are currently being used off-label. The future direction of the development of tocolytics agents should be directed toward better efficacy in intentionally prolonging pregnancy. This will potentially result in less maternal, fetal, and neonatal adverse effects when delaying preterm childbirth. A few tocolytic alternatives worth pursuing include [[Barusiban]], a last generation of oxytocin receptor antagonists, as well as [[COX-2 inhibitor]]s.<ref>{{Cite journal|last1=Hubinont|first1=C.|last2=Debieve|first2=F.|date=2011|title=Prevention of Preterm Labour: 2011 Update on Tocolysis|journal=Journal of Pregnancy|language=en|volume=2011|page=941057|doi=10.1155/2011/941057|pmid=22175022|pmc=3228310|issn=2090-2727|doi-access=free}}</ref> More studies on the use of multiple tocolytics must be directed to research overall health outcomes rather than solely pregnancy prolongation.<ref>{{Cite journal|last1=Cole|first1=Stephen|last2=Smith|first2=Roger|last3=Giles|first3=Warwick|date=2004|title=Tocolysis: current controversies, future directions|url=https://pubmed.ncbi.nlm.nih.gov/15134284|journal=Current Opinion in Investigational Drugs |volume=5|issue=4|pages=424–429|issn=1472-4472|pmid=15134284}}</ref>